Research in renal physiology
Conditions
Interventions
None listed
Sponsors
Dr. D.H. van Raalte Department of Endocrinology, VUMC/AMC De Boelelaan 1117, 1081 HV, Amsterdam E-mail: d.vanraalte@amsterdamumc.nl
Eligibility
Inclusion criteria
Inclusion criteria: In order to be eligible to participate in this study, a subject must meet all of the following criteria: - Diagnosed with gender dysphoria according to DSM-V (transmen or transwomen) - Age between 18 and 30 years - Expected to start cross-sex hormone treatment in the upcoming month
Exclusion criteria
Exclusion criteria: A potential subject who meets any of the following criteria will be excluded from participation in this study: - Current use of sex hormones - Participation in other studies - Concomitant use of medication (specifically: blood pressure lowering products, anti-depressants, anti-psychotic agents or medication prescribed for the treatment of attention deficit hyperactivity disorder), - Known kidney disease (eGFR 2,5 mg/mmol) - Diabetes mellitus - A history of cardiovascular disease (myocardial infarction; cardiac surgery or revascularization, unstable angina, heart failure, transient ischemic attack, cerebrovascular disease or a previously undiagnosed arrhythmia - Known iodine related allergies
Design outcomes
Secondary
| Measure | Time frame |
|---|---|
| Secondary endpoints are the estimation of intrarenal hemodynamic parameters derived from Gomez equations, markers of tubular injury and changes in systemic hemodynamic properties. Additionally, the M-value as a marker of insulin sensitivity will be determined using a hyperinsulinemic euglycemic clamp technique. | — |
Primary
| Measure | Time frame |
|---|---|
| The main study parameters/endpoints are the measurement of glomerular filtration rate (GFR) and effective renal plasma flow (ERPF) as measured by iohexol and p-amminohippurate (PAH) clearance. | — |
Contacts
Public ContactSarah van Eeghen
VUmc
Outcome results
None listed